Valneva reports further positive phase 2 safety and immunogenicity results for lyme disease vaccine candidate

Saint-herblain (france), september 3 rd , 2025 – valneva se (nasdaq: valn; euronext paris: vla) announced positive immunogenicity and safety data from the ongoing phase 2 study of lyme disease vaccine candidate, vla15. the strong anamnestic immune response and favorable safety profile following a third booster dose were consistent with those reported after receiving previous annual booster doses1 , 2 further demonstrating compatibility with the anticipated benefits of a yearly vaccination prior to each lyme season.
VALN Ratings Summary
VALN Quant Ranking